BlackRock
RNAC icon

BlackRock’s Cartesian Therapeutics RNAC Stock Holding History

BlackRock’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.68M Sell
599,108
-10,588
-2% -$75.4K ﹤0.01% 3944
2025
Q4 		$4.4M Sell
609,696
-39,645
-6% -$321K ﹤0.01% 3883
2025
Q3 		$6.64M Sell
649,341
-4,499
-0.7% -$50.6K ﹤0.01% 3647
2025
Q2 		$6.79M Sell
653,840
-19,210
-3% -$205K ﹤0.01% 3615
2025
Q1 		$8.87M Buy
673,050
+13,648
+2% +$244K ﹤0.01% 3374
2024
Q4 		$11.8M Buy
659,402
+235,936
+56% +$4.78M ﹤0.01% 3342
2024
Q3 		$6.83M Buy
423,466
+15,870
+4% +$248K ﹤0.01% 3581
2024
Q2 		$11M Buy
407,596
+165,797
+69% +$3.96M ﹤0.01% 3336
2024
Q1 		$4.72M Sell
241,799
-8,799
-4% -$187K ﹤0.01% 3692
2023
Q4 		$5.18M Sell
250,598
-7,575
-3% -$226K ﹤0.01% 3679
2023
Q3 		$8.21M Sell
258,173
-4,531
-2% -$151K ﹤0.01% 3449
2023
Q2 		$8.83M Buy
262,704
+182,434
+227% +$6.53M ﹤0.01% 3473
2023
Q1 		$3.35M Sell
80,270
-1,838
-2% -$86.4K ﹤0.01% 3812
2022
Q4 		$2.78M Buy
82,108
+1,495
+2% +$63.6K ﹤0.01% 3990
2022
Q3 		$3.96M Buy
80,613
+1,457
+2% +$80K ﹤0.01% 3855
2022
Q2 		$3.11M Sell
79,156
-146,339
-65% -$4.34M ﹤0.01% 4038
2022
Q1 		$8.32M Sell
225,495
-6,234
-3% -$390K ﹤0.01% 3674
2021
Q4 		$22.7M Sell
231,729
-458
-0.2% -$49.3K ﹤0.01% 3193
2021
Q3 		$29M Buy
232,187
+9,154
+4% +$1.11M ﹤0.01% 3040
2021
Q2 		$28M Buy
223,033
+14,963
+7% +$1.78M ﹤0.01% 3093
2021
Q1 		$28.2M Buy
208,070
+25,593
+14% +$3.18M ﹤0.01% 2987
2020
Q4 		$16.6M Buy
182,477
+35,302
+24% +$3.06M ﹤0.01% 3106
2020
Q3 		$10.9M Buy
147,175
+15,252
+12% +$1.17M ﹤0.01% 3173
2020
Q2 		$11.2M Buy
131,923
+108,744
+469% +$9.86M ﹤0.01% 3115
2020
Q1 		$1.68M Buy
23,179
+1,211
+6% +$117K ﹤0.01% 3712
2019
Q4 		$1.57M Sell
21,968
-436
-2% -$21K ﹤0.01% 3857
2019
Q3 		$1.18M Buy
22,404
+143
+0.6% +$7.6K ﹤0.01% 3922
2019
Q2 		$1.2M Sell
22,261
-34,138
-61% -$2.33M ﹤0.01% 3957
2019
Q1 		$4.01M Buy
56,399
+26,446
+88% +$1.68M ﹤0.01% 3487
2018
Q4 		$2.39M Buy
29,953
+37
+0.1% +$8.44K ﹤0.01% 3613
2018
Q3 		$14M Buy
29,916
+431
+1% +$173K ﹤0.01% 3064
2018
Q2 		$11.7M Buy
29,485
+8,486
+40% +$3.01M ﹤0.01% 3158
2018
Q1 		$6.42M Buy
20,999
+325
+2% +$92.6K ﹤0.01% 3319
2017
Q4 		$6.08M Buy
20,674
+1,375
+7% +$601K ﹤0.01% 3362
2017
Q3 		$10.6M Buy
19,299
+2,616
+16% +$1.39M ﹤0.01% 3139
2017
Q2 		$9.94M Buy
16,683
+9,730
+140% +$4.3M ﹤0.01% 3171
2017
Q1 		$2.99M Buy
6,953
+6,947
+115,783% +$2.92M ﹤0.01% 3542
2016
Q4 		$3K Buy
+6
New +$3.51K ﹤0.01% 3594

Other funds holding RNAC

Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return

BlackRock's RNAC Position: Q1 2026 in Review

BlackRock reduced its Cartesian Therapeutics (RNAC) stake by 1.7% in Q1 2026, selling an estimated $75.4K and leaving 599,108 shares worth $3.68M. The position accounts for ﹤0.01% of the portfolio, ranked #3944.

BlackRock first reported a position in RNAC in Q4 2016 and has held it in 38 quarters since. The position peaked at $29M in Q3 2021. 83 funds tracked by Wall St. Rank hold RNAC as of Q1 2026.

  • BlackRock held 599,108 shares of Cartesian Therapeutics worth $3.68M as of Q1 2026.
  • BlackRock sold 10,588 Cartesian Therapeutics shares in Q1 2026, an estimated $75.4K.
  • Cartesian Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q1 2026, its #3944 holding.
  • BlackRock first reported a position in Cartesian Therapeutics in Q4 2016 and has held it in 38 quarters since.
  • BlackRock's Cartesian Therapeutics position peaked at $29M in Q3 2021.
  • 83 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q1 2026.

Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.